Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers.
Antibody suspension bead array
Biomarkers
Cerebrospinal fluid
Frontotemporal dementia
Proteomics
Journal
Translational neurodegeneration
ISSN: 2047-9158
Titre abrégé: Transl Neurodegener
Pays: England
ID NLM: 101591861
Informations de publication
Date de publication:
23 06 2020
23 06 2020
Historique:
received:
27
11
2019
accepted:
07
05
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
20
7
2021
Statut:
epublish
Résumé
The clinical presentations of frontotemporal dementia (FTD) are diverse and overlap with other neurological disorders. There are, as of today, no biomarkers in clinical practice for diagnosing the disorders. Here, we aimed to find protein markers in cerebrospinal fluid (CSF) from patients with FTD, presymptomatic mutation carriers and non-carriers. Antibody suspension bead arrays were used to analyse 328 proteins in CSF from patients with behavioural variant FTD (bvFTD, n = 16) and progressive primary aphasia (PPA, n = 13), as well as presymptomatic mutation carriers (PMC, n = 16) and non-carriers (NC, n = 8). A total of 492 antibodies were used to measure protein levels by direct labelling of the CSF samples. The findings were further examined in an independent cohort including 13 FTD patients, 79 patients with Alzheimer's disease and 18 healthy controls. We found significantly altered protein levels in CSF from FTD patients compared to unaffected individuals (PMC and NC) for 26 proteins. The analysis show patterns of separation between unaffected individuals and FTD patients, especially for those with a clinical diagnosis of bvFTD. The most statistically significant differences in protein levels were found for VGF, TN-R, NPTXR, TMEM132D, PDYN and NF-M. Patients with FTD were found to have higher levels of TN-R and NF-M, and lower levels of VGF, NPTXR, TMEM132D and PDYN, compared to unaffected individuals. The main findings were reproduced in the independent cohort. In this pilot study, we show a separation of FTD patients from unaffected individuals based on protein levels in CSF. Further investigation is required to explore the CSF profiles in larger cohorts, but the results presented here has the potential to enable future clinical utilization of these potential biomarkers within FTD.
Sections du résumé
BACKGROUND
The clinical presentations of frontotemporal dementia (FTD) are diverse and overlap with other neurological disorders. There are, as of today, no biomarkers in clinical practice for diagnosing the disorders. Here, we aimed to find protein markers in cerebrospinal fluid (CSF) from patients with FTD, presymptomatic mutation carriers and non-carriers.
METHODS
Antibody suspension bead arrays were used to analyse 328 proteins in CSF from patients with behavioural variant FTD (bvFTD, n = 16) and progressive primary aphasia (PPA, n = 13), as well as presymptomatic mutation carriers (PMC, n = 16) and non-carriers (NC, n = 8). A total of 492 antibodies were used to measure protein levels by direct labelling of the CSF samples. The findings were further examined in an independent cohort including 13 FTD patients, 79 patients with Alzheimer's disease and 18 healthy controls.
RESULTS
We found significantly altered protein levels in CSF from FTD patients compared to unaffected individuals (PMC and NC) for 26 proteins. The analysis show patterns of separation between unaffected individuals and FTD patients, especially for those with a clinical diagnosis of bvFTD. The most statistically significant differences in protein levels were found for VGF, TN-R, NPTXR, TMEM132D, PDYN and NF-M. Patients with FTD were found to have higher levels of TN-R and NF-M, and lower levels of VGF, NPTXR, TMEM132D and PDYN, compared to unaffected individuals. The main findings were reproduced in the independent cohort.
CONCLUSION
In this pilot study, we show a separation of FTD patients from unaffected individuals based on protein levels in CSF. Further investigation is required to explore the CSF profiles in larger cohorts, but the results presented here has the potential to enable future clinical utilization of these potential biomarkers within FTD.
Identifiants
pubmed: 32576262
doi: 10.1186/s40035-020-00198-y
pii: 10.1186/s40035-020-00198-y
pmc: PMC7310563
doi:
Substances chimiques
Biomarkers
0
Cerebrospinal Fluid Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Subventions
Organisme : JPND Prefrontals Swedish Research Council (VR)
ID : 529-2014-7504
Pays : International
Organisme : Swedish Research Council (VR)
ID : 2015-02926
Pays : International
Organisme : Swedish Research Council (VR)
ID : 2018-02754
Pays : International
Références
Clin Chem Lab Med. 2015 Sep 1;53(10):1575-84
pubmed: 25720124
Neurology. 2003 Apr 8;60(7):1094-7
pubmed: 12682312
Exp Neurol. 2005 Dec;196(2):273-81
pubmed: 16154129
Nat Rev Neurol. 2018 Jun;14(6):363-378
pubmed: 29777184
Bioinformatics. 2018 Mar 01;34(5):721-724
pubmed: 29088312
N Engl J Med. 2012 Aug 30;367(9):795-804
pubmed: 22784036
Neuroscience. 2001;104(2):359-69
pubmed: 11377840
Eur J Neurosci. 2008 Mar;27(6):1373-90
pubmed: 18364019
Hum Mutat. 2013 Feb;34(2):363-73
pubmed: 23111906
Alzheimers Res Ther. 2018 Jan 15;10(1):5
pubmed: 29370833
Proteomics Clin Appl. 2016 Dec;10(12):1242-1253
pubmed: 27604409
Neuron. 2011 Oct 20;72(2):257-68
pubmed: 21944779
Proteomics. 2013 Aug;13(15):2256-67
pubmed: 23696371
Genes Brain Behav. 2003 Feb;2(1):20-31
pubmed: 12882316
PLoS One. 2015 Aug 13;10(8):e0135365
pubmed: 26270474
J Neurosci. 2009 Oct 21;29(42):13377-88
pubmed: 19846725
Neurodegener Dis. 2014;13(2-3):82-5
pubmed: 23970097
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Nat Rev Neurol. 2017 Jul;13(7):406-419
pubmed: 28621768
Neurobiol Aging. 2005 Feb;26(2):207-27
pubmed: 15582749
J Proteomics. 2013 Dec 16;95:46-54
pubmed: 23631827
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 28373358
Behav Brain Res. 2003 Oct 17;145(1-2):189-207
pubmed: 14529817
J Alzheimers Dis. 2016 Nov 19;55(2):625-644
pubmed: 27716663
Methods Mol Biol. 2019;2044:303-318
pubmed: 31432421
Pharmacol Ther. 2009 Sep;123(3):353-70
pubmed: 19481570
J Proteome Res. 2008 Aug;7(8):3168-79
pubmed: 18588325
Neuropsychology. 1999 Jan;13(1):31-40
pubmed: 10067773
Proteomics Clin Appl. 2018 Jan;12(1):
pubmed: 29028155
Lancet. 2015 Oct 24;386(10004):1672-82
pubmed: 26595641
Rev Neurol (Paris). 2013 Oct;169(10):820-4
pubmed: 24012408
J Biochem. 2003 Aug;134(2):231-8
pubmed: 12966072
Neuron. 2011 Oct 20;72(2):245-56
pubmed: 21944778
Neurology. 2014 Nov 18;83(21):1945-53
pubmed: 25339208
Ann Clin Transl Neurol. 2014 Aug;1(8):544-53
pubmed: 25356426
J Neurol. 2013 Mar;260(3):856-9
pubmed: 23108490
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
J Neurosci Res. 2000 Apr 1;60(1):21-36
pubmed: 10723065
Neurology. 2010 Dec 7;75(23):2079-86
pubmed: 21048198
JAMA Neurol. 2019 Jun 17;:
pubmed: 31206160
Transl Psychiatry. 2012 Sep 04;2:e156
pubmed: 22948381
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
J Neurosci. 2012 Oct 31;32(44):15388-402
pubmed: 23115177
Ann Clin Transl Neurol. 2019 Mar 07;6(4):698-707
pubmed: 31019994
Neurobiol Aging. 2007 Nov;28(11):1700-8
pubmed: 16914231
Nature. 2006 Aug 24;442(7105):916-9
pubmed: 16862116
J Neurocytol. 2001 Apr;30(4):293-301
pubmed: 11875277
Nature. 1998 Jun 18;393(6686):702-5
pubmed: 9641683
Neurology. 2009 Nov 3;73(18):1451-6
pubmed: 19884572
Exp Gerontol. 2012 Apr;47(4):323-8
pubmed: 22532968
Lancet Neurol. 2015 Mar;14(3):253-62
pubmed: 25662776
Exp Mol Med. 2013 Sep 06;45:e39
pubmed: 24008896
Ann Clin Transl Neurol. 2016 Jul 01;3(8):623-36
pubmed: 27606344
Nature. 2006 Aug 24;442(7105):920-4
pubmed: 16862115
J Alzheimers Dis. 2019;67(2):639-651
pubmed: 30614806
Neurobiol Aging. 2019 Dec;84:241.e21-241.e25
pubmed: 30992141
Am J Pathol. 2012 Feb;180(2):446-56
pubmed: 22122984
Clin Chim Acta. 2019 Jul;494:79-93
pubmed: 30858094
Acta Neuropathol. 2020 Jan;139(1):119-134
pubmed: 31701227
Ann Neurol. 2014 Jan;75(1):116-26
pubmed: 24242746
Proteomics. 2019 Aug;19(15):e1900008
pubmed: 31278833
J Neural Transm (Vienna). 2009 Jul;116(7):897-903
pubmed: 19468819